![]() |
Name |
6-Oxododecanedioic acid
|
Molecular Formula | C12H20O5 | |
IUPAC Name* |
6-oxododecanedioic acid
|
|
SMILES |
C(CCC(=O)CCCCC(=O)O)CCC(=O)O
|
|
InChI |
InChI=1S/C12H20O5/c13-10(7-4-5-9-12(16)17)6-2-1-3-8-11(14)15/h1-9H2,(H,14,15)(H,16,17)
|
|
InChIKey |
KYEKIBGSYFYOIE-UHFFFAOYSA-N
|
|
Synonyms |
6-Oxododecanedioic acid
|
|
CAS | NA | |
PubChem CID | 581087 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 244.28 | ALogp: | 0.8 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 11 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 91.7 | Aromatic Rings: | 0 |
Heavy Atoms: | 17 | QED Weighted: | 0.545 |
Caco-2 Permeability: | -5.739 | MDCK Permeability: | 0.00001480 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.006 |
Human Intestinal Absorption (HIA): | 0.23 | 20% Bioavailability (F20%): | 0.054 |
30% Bioavailability (F30%): | 0.118 |
Blood-Brain-Barrier Penetration (BBB): | 0.017 | Plasma Protein Binding (PPB): | 72.21% |
Volume Distribution (VD): | 0.316 | Fu: | 22.13% |
CYP1A2-inhibitor: | 0.007 | CYP1A2-substrate: | 0.069 |
CYP2C19-inhibitor: | 0.017 | CYP2C19-substrate: | 0.041 |
CYP2C9-inhibitor: | 0.008 | CYP2C9-substrate: | 0.976 |
CYP2D6-inhibitor: | 0.011 | CYP2D6-substrate: | 0.128 |
CYP3A4-inhibitor: | 0.005 | CYP3A4-substrate: | 0.006 |
Clearance (CL): | 2.835 | Half-life (T1/2): | 0.907 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.145 |
Drug-inuced Liver Injury (DILI): | 0.065 | AMES Toxicity: | 0.02 |
Rat Oral Acute Toxicity: | 0.002 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.05 | Carcinogencity: | 0.038 |
Eye Corrosion: | 0.93 | Eye Irritation: | 0.851 |
Respiratory Toxicity: | 0.034 |